Search CJC-1295 before and after and you get shirtless photos. The controlled human record measured something else entirely: blood. Two 2006 trials tracked growth hormone and IGF-1 for 28 and 49 days, and never scanned a body.
CJC-1295 has no before-and-after trial. The published data measured blood, not bodies. Two 2006 studies ran 28 and 49 days. Growth hormone rose 2- to 10-fold. IGF-1 rose 1.5- to 3-fold. Nobody was weighed, scanned or photographed.
What a CJC-1295 study actually measured
The controlled human record for CJC-1295 is two placebo-controlled dose-ranging trials published in 2006. They ran 28 and 49 days. Healthy adults received it under the skin at 30 to 60 µg/kg, with higher arms tested and tolerated less well.
What those trials measured was serum.
- Growth hormone. Mean levels rose 2- to 10-fold after dosing, with peaks reported up to 7.5-fold.
- IGF-1. Rose 1.5- to 3-fold and stayed elevated for days.
- Half-life. The DAC version persisted 6 to 8 days. The no-DAC version clears in about 30 minutes.
- Tolerability. No serious adverse reactions were reported in either trial at the lower doses.
There was no DEXA scan. No body weight endpoint. No waist measurement, no skinfolds, no strength testing, no photographs. The trials were built to answer whether the molecule raises a hormone, and they answered that.
A hormone level is an input, not an outcome. Knowing that IGF-1 went up 1.5- to 3-fold tells you the drug reached the pituitary. It does not tell you what happened to fat, muscle, skin or sleep, because those were never recorded.
The mechanism itself is well described. See how CJC-1295 hits the GHRH receptor and the side effect record from those same two trials.
Why no photograph has a trial behind it
Zero randomized controlled trials have tested CJC-1295 for muscle, fat loss or aging endpoints. Not since 2006, and not since 2020 in any form.
That is not because the compound vanished from the literature. It is because the literature that exists is about catching it. Four major detection-methods papers from 2021 to 2024 describe how anti-doping labs pull GHRH analogs out of urine: Memdouh and colleagues in Drug Testing and Analysis, Coppieters in the Journal of Pharmaceutical and Biomedical Analysis, Cristea in Analytical Biochemistry, and Thomas in the Journal of Mass Spectrometry.
Those are assay papers. They exist because athletes use the compound, and they measure detection windows, not deltoids. WADA lists CJC-1295 under S2.
Many peptides marketed for performance and recovery have not been evaluated in randomized controlled trials, and their safety in healthy athletes remains uncharacterized.
Mendias & Awan, Sports Medicine, 2026Use of these agents in recreational and professional bodybuilding is driven largely by anecdotal report rather than by controlled clinical evidence.
Coutinho et al., Journal of Sports Medicine and Physical Fitness, 2026Sinha and colleagues, writing in Translational Andrology and Urology in 2020, reviewed growth hormone secretagogues for body composition in hypogonadal men and reached the same place: interesting class, thin human evidence. The full development history is in the CJC-1295 complete guide.
The GHRH analog that did get a real before and after
This is the useful comparison. Tesamorelin is a 44 amino acid GHRH analog, and it did what CJC-1295 never did: it went through registration trials with imaging endpoints in people.
| Compound | Study | What was measured |
|---|---|---|
| CJC-1295 | 2006 dose-ranging, 28 and 49 days | Serum GH and IGF-1 only |
| Tesamorelin | Russo et al., AIDS, 2024 | Visceral fat in people with HIV on integrase inhibitors |
| Tesamorelin | Fourman et al., JCI Insight, 2020 | Liver fat and hepatic gene expression in HIV-associated NAFLD |
| Tesamorelin | Ellis et al., Journal of Infectious Diseases, 2025 | Neurocognitive testing with abdominal obesity |
Those studies scanned abdomens and biopsied livers. Whatever you think of the effect sizes, the endpoints were physical. The CJC-1295 endpoint was a blood draw.
The trade is cost. Prescribed tesamorelin runs about $3,500–5,000 a month. Research-grade CJC-1295 sells for roughly $80–120 a vial. That price gap is most of why the search volume sits where it does. The molecules are compared side by side in CJC-1295 vs tesamorelin.
CJC-1295
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Most before-and-after photos are not of CJC-1295 alone
The stocked product almost everyone is photographing is a blend. A 10 mg vial holding 5 mg of each: CJC-1295 and ipamorelin, in a fixed ratio.
No trial has ever administered the two together. Not one. So even if a photo were honest, complete and unedited, it could not tell you which molecule did anything.
- Two compounds, one image. Ipamorelin is a 5-amino-acid ghrelin mimic working through a different receptor.
- Two versions of one compound. DAC and no-DAC behave nothing alike, and photos rarely say which was used.
- Everything else in the frame. Training block, calorie deficit, creatine, lighting, tan, posture, time of day.
Despite growing clinical interest, high-quality evidence supporting injectable peptide therapy remains limited, and physicians should counsel patients accordingly.
Mayfield et al., American Journal of Sports Medicine, 2026What each half of the blend has actually been given in a study is set out in the CJC-1295 and ipamorelin dosage page.
What would make a before and after worth reading
A photo of a lean person is not data. A record of measurements taken the same way twice is closer to it. If someone is going to publish a personal result, these are the things that would let a reader check it.
- A serum IGF-1 draw before and after. That is the endpoint the 2006 trials used, and the only one with a published comparison.
- A body composition scan, not a mirror. DEXA or the same clinic's device on both dates.
- The diet and training log. A calorie deficit produces the photo on its own. Two arms dieting is how AOD-9604 stopped separating from placebo.
- Which compound, at what purity. A batch certificate of analysis names the peptide and its measured purity.
Mavrych and colleagues, reviewing therapeutic peptides in Frontiers in Aging in 2026, place GHRH analogs among the mechanistically plausible candidates for healthy aging. Plausible is where CJC-1295 currently sits. It has not moved past it in twenty years.
Nothing on this page is an instruction to use anything. CJC-1295 is a research chemical, not an approved drug, and it is banned in competition. Reported IGF-1 changes from a dose-ranging study are not a promised result.
CJC-1295
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- The only controlled CJC-1295 data are two 2006 dose-ranging trials, lasting 28 and 49 days.
- Those trials measured serum GH and IGF-1. No weight, no DEXA, no waist, no photographs.
- GH rose 2- to 10-fold and IGF-1 rose 1.5- to 3-fold. Neither is a body composition outcome.
- Zero randomized trials have tested CJC-1295 for muscle, fat loss or aging endpoints.
- Most photos show a CJC-1295 plus ipamorelin blend, a combination no study has ever administered.
- Tesamorelin, a related GHRH analog, does have imaging endpoints in published trials. CJC-1295 does not.
What we're watching
The thing to watch for is a registered trial of CJC-1295 with a physical endpoint: body composition, strength, or imaging. None has been published since the 2006 dose-ranging studies, and the 2021-2024 literature is dominated by anti-doping detection methods rather than efficacy.
Frequently asked questions
Are there real CJC-1295 before and after results?
Not in the published literature. The 2006 trials measured growth hormone and IGF-1 in blood over 28 and 49 days. No body weight, body fat or strength endpoint was recorded, so there is no measured physical before and after to compare a photograph against.
How long did the published trials run?
28 and 49 days. Both were placebo-controlled dose-ranging studies in healthy adults, and both ended with serum measurements. Nothing longer has been published since.
Did IGF-1 actually go up?
Yes. IGF-1 rose roughly 1.5- to 3-fold and stayed elevated for days after dosing, and growth hormone rose 2- to 10-fold. Those are hormone levels, not results in tissue.
Why do most photos show the CJC-1295 and ipamorelin blend?
Because that is what is sold. A 10 mg vial typically holds 5 mg of each. No trial has ever given the two together, so any change seen cannot be attributed to either one.
Is CJC-1295 detectable in a drug test?
Yes. Four major detection-methods papers from 2021 to 2024 describe mass spectrometry assays for GHRH analogs in urine, and WADA lists CJC-1295 under S2.
Is CJC-1295 approved for body composition?
No. It is not an approved drug in any country and never completed Phase III. Tesamorelin, a different GHRH analog, is the one with registration trials that used imaging endpoints.
References
- Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
- Mavrych, V., Shypilova, I., & Bolgova, O. (2026). Therapeutic peptides in gerontology: Mechanisms and applications for healthy aging. Frontiers in Aging, 7, 1790247. https://doi.org/10.3389/fragi.2026.1790247
- Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding. Journal of Sports Medicine and Physical Fitness. https://doi.org/10.23736/S0022-4707.26.17773-1
- Mayfield, C. K., Bolia, I. K., Feingold, C. L., et al. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
- Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
- Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
- Coppieters, G., Deventer, K., Polet, M., Van Eenoo, P., & Judák, P. (2022). An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine. Journal of Pharmaceutical and Biomedical Analysis, 214, 114726. https://doi.org/10.1016/j.jpba.2022.114726
- Cristea, C. D., Radu, M., Toboc, A., Stan, C., & David, V. (2023). Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Analytical Biochemistry, 682, 115336. https://doi.org/10.1016/j.ab.2023.115336
- Thomas, A., Walpurgis, K., & Thevis, M. (2024). Chromatographic-mass spectrometric analysis of peptidic analytes in doping control urine samples. Journal of Mass Spectrometry, 59(1), e4996. https://doi.org/10.1002/jms.4996
- Rahman, O. F., Lee, S. J., & Seeds, W. A. (2026). Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 10(1). https://doi.org/10.5435/JAAOSGlobal-D-25-00236
- Russo, S. C., Ockene, M. W., Arpante, A. K., et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://doi.org/10.1097/QAD.0000000000003965
- Fourman, L. T., Billingsley, J. M., Agyapong, G., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16). https://doi.org/10.1172/jci.insight.140134
- Ellis, R. J., Vaida, F., Hu, K., et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012